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Background: This study aimed to investigate if treatment response could retro-
spectively be related to inﬂammatory or axonal pathology as measured by plasma
surrogate markers.
Methods: In this 1–year observational study 30 MS patients with relapsing–
remitting disease were treated with intra–muscular IFN–1a or subcutaneous IFN–
1b. Responders and non–responders were deﬁned according to clinical and MRI cri-
teria. The control group consisted of 14 healthy subjects. Plasma levels of surrogate
markers for inﬂammation (nitric oxide metabolites (NOx )), astrocytic activation
(S100B) and axonal damage (NfHSMI35 ) were measured using standard assays.
Results: There were 11 non–responders and 19 responders to IFN treatment.
Median S100B levels were elevated in a higher proportion of treatment responders
(63%, 42.9 pg/mL) compared to non–responders (18%, 11.7 pg/mL, p<0.05, Fisher’s
exact test) and controls (0%, 2 pg/mL, p< 0.001). Levels of NOx were found to be
more frequently elevated in non–responders (72%, 39 M) compared to healthy
controls (0%, 37 M, p<0.05). Levels of NfHSMI35 were more frequently elevated
in responders (58%, 300 pg/mL, p<0.001) and non–responders (72%, 500 pg/mL,
p<0.001) compared to controls (0%, 4.5 pg/mL).
Conclusion: Patients with relapsing–remitting MS who had surrogate marker sup-
ported evidence for astrocytic activation responded more frequently to treatment
with IFN.
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21 Introduction
Characterising responders and non-responders to treatment in multiple scle-
rosis (MS) is of relevance for understanding disease progression and selecting
eﬀective drug treatment strategies. MS is a heterogeneous disease [1] and it
was suggested that the heterogeneity of treatment response could be related to
the underlying pathology [2]. Particularly inﬂammation has been associated
with relapses, and relapse frequency early on is related to disease progression.
The proven beneﬁt common to all currently recommended treatments is a re-
duction in the rate of clinical relapse, which has been associated to a transient
slowing of disease progression [3]. During the early phase of MS active disease
has been related to elevated levels of S100B [4] and the nitric oxide metabolites
nitrate and nitrite (NOx ) [5].
The hypothesis underlying this study was that patients who responded to
IFN treatment would be diﬀerent from non–responders with regard to their
proﬁle of plasma inﬂammatory (NOx ), astrocytic activation (S100B) and ax-
onal (NfHSMI35 ) markers.
2 Materials and methods
2.1 Patients
Thirty patients with relapsing remitting multiple sclerosis (RRMS) [6] were
included in this cross–sectional study. All patients were treated with IFN and
recruited from the MS specialist clinic at the Toulouse Purpan Hptial between
March 2000 and November 2001. The control group consisted of 14 healthy
volunteers. All plasma samples were obtained by antecubital venopuncture at
the last clinical assessment. Samples were coded and stored at -70C until anal-
ysis. Approval for the study was obtained from the local Ethics Committees.
Written informed consent was obtained from each subject.
2.2 Clinical assessment
All patients were assessed by two experienced neurologists (DB, MC). The ex-
panded Disability Status Scale score (EDSS) and the yearly relapse frequency
prior to sampling were recorded.
It was decided to declare treatment failure based on clinical and MRI criteria
(when available). Patients who suﬀered from at least two clinical relapses as-
3sociated with at least one gadolinium-enhancing lesion on T1 MRI performed
at least one month after steroid treatment (“active MRI”), or patients who
progressed by over 1 point on the EDSS associated with an active MRI.
2.3 Assays
Plasma levels of S100B, NOx and NfHSMI35 were measured using standard as-
says) as described previously [7,8,9,10]. The cutoﬀ value for abnormal levels
of these biomarkers were deﬁned as the top value of the control group.
2.4 Statistical Analysis
All statistical analyses and graphs were done using SAS software (V8.2, SAS
Institute, Inc., Cary, North Carolina, USA). Because of the non–Gaussian
distribution all data is presented as the median and interquartile range (IQR).
The box (median and 25%-75% cumulative frequency) and whisker (1%-100%
cumulative frequency) are shown in the graphs. Because of the small sample
size Fisher’s exact test was used for comparison of proportions of patients.
The linear relationship between continuous variables was evaluated using the
non–parametric Spearman correlation coeﬃcient (=0.05).
3 Results
The baseline characteristic of the MS patients are summarised in Table 1. Ac-
cording to our deﬁnition there were 11 responder and 19 non–responder. Pa-
tients with MS were signiﬁcantly younger than the control patients and there
were more females. There were no signiﬁcant diﬀerences between responder
and non–responder with regard to the EDSS. The choice of the generic drug
was not related to treatment response.
The plasma levels for S100B, NOx and NfHSMI35 (median, range) are sum-
marised in Table 1. The cutoﬀ levels were determined as the top value from
the control group (S100B = 33 pg/mL, NOx = 44 M, NfHSMI35 = 250 pg/mL).
In all non–responders MRI was performed. Although a subgroup of responder
(n=16) received an MRI brain scan. However the timing of MRI brain scan
to relapse and plasma sampling was not rigorous.
A signiﬁcantly higher proportion of responders (63%) but not of non-responders
(18%) had S100B levels above cut–oﬀ compared to controls (p=0.021). The
4individual values are shown in Figure 1. There were 2 outliers with plasma
S100B levels over 300 pg/mL among the responders (Figure 1). Removal of
these 2 outliers did not alter statistical signiﬁcance (p=0.034, Fisher’s exact
test).
A signiﬁcant proportion of non–responders (45%) had NOx levels above cutoﬀ.
Also a signiﬁcant proportion of responders (58%) and non–responders (72%)
had NfHSMI35 levels above cutoﬀ. There was no signiﬁcant diﬀerence compar-
ing proportions of responders and non–responders for either NOx or NfHSMI35 .
There was no correlation between age, EDSS, relapse frequency and either
S100B, NOx or NfHSMI35 for any of the subgroups.
4 Discussion
This study found higher plasma levels S100B, NOx and NfHSMI35 in patients
with MS than in healthy controls. In treatment responders the median S100B
levels were over 3–fold higher than in non–responders.
We and others previously related elevated CSF S100B to acute disease activity
in MS [4]. It is therefore diﬃcult to understand if not paradoxic that treatment
responders should have higher plasma S100B levels. A major criticism of this
study is the retrospective, the cross–sectional design and the lack of MRI data
in some of the patients. However in a longitudinal study on serum S100B in
primary progressive MS patients from a clinically negative phase II trial we
found similar levels in the non–responders (E Lim, unpublished data).
The current understanding is that IFN– reduces disease activity by exerting
immunomodulatory properties. However in vivo and in vitro data shows up-
regulation of pro–inﬂammatory factors during IFN– treatment [11]. On the
background that inﬂammation has been related to protective and destructive
mechanisms [12] it can be speculated that these properties might be related
in degree to a spectrum of severity. Severe inﬂammation, blood–brain barrier
(BBB) disruption and neutrophil invasion were all related to tissue destruction
[13]. Indeed there was a trend for higher NfHSMI35 levels in non–responder. Pre-
viously we have shown that particular the combination of inﬂammation with
axonal damage indicated poorer prognosis [14].
However low grade inﬂammation orchestrated by the macrophage and micro–
glial network could be neuroprotective. In vitro data supports this notion
in as nanomolar levels of S100B are neurotrophic [15]. This suggests that
moderately elevated S100B levels might be beneﬁcial in the context of IFN–
eﬀects on BBB integrity and inhibition of more severe steps of inﬂammatory
5activity such as T–cell invasion and subsequent neuro–axonal degeneration.
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7Table 1: Demographic characteristics of patients classiﬁed according to clinical criteria of
treatment failure. The relapse frequency is given in number of relapses per year. The age
and disease duration are given in years. Levels of plasma S100B, NOx , NfHSMI35 median
(range) in patients based on clinical criteria of treatment failure. Statistical comparisons
are indicated in the following order: control versus non–responder; controls versus respon-
der; non–responder versus responder. NS = not signiﬁcant.
Control MS patients
Non–responder Responder P value
Number 14 11 (37%) 19 (63%)
Age 36 (24–59) 26 (23–42) 33 (19–40) <0.05; <0.05; NS
Sex (F:M) 8:6 9:2 16:3 NS
Relapse frequency N/A 2 (2–8) 1 (0–1) <0.001
Disease duration N/A 8 (2–14) 7 (1–18) NS
EDSS N/A 3.5 (1.0–6.5) 3.5 (1.5–6.5) NS
IFN 1a n (%) N/A 1 (9%) 3 (16%)
IFN 1b n (%) N/A 10 (91%) 16 (84%)
S100B (pg/mL) 2 (0–11) 11.7 (0.1–53.2) 42.9 (16.5–483.0) NS; <0.001; <0.05
NOx (M) 37 (35–39) 42.4 (25.2–74.5) 39 (17.3–81.0) 0.01; NS; NS
































Figure 1. Plasma S100B (pg/mL) levels in normal controls, treatment non–respon-
ders and treatment responders. The dotted horizontal line indicates the cutoﬀ of 33
pg/mL (100% cumulative frequency of the control group).
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